Histology-specific microRNA alterations in melanoma.

PubWeight™: 0.99‹?› | Rank: Top 15%

🔗 View Article (PMC 3648670)

Published in J Invest Dermatol on May 03, 2012

Authors

Laura Poliseno1, Adele Haimovic, Miguel F Segura, Douglas Hanniford, Paul J Christos, Farbod Darvishian, Jinhua Wang, Richard L Shapiro, Anna C Pavlick, Russell S Berman, Eva Hernando, Jiri Zavadil, Iman Osman

Author Affiliations

1: The Ronald O. Perelman Department of Dermatology, New York University School of Medicine, New York, New York, USA.

Articles citing this

In-depth characterization of microRNA transcriptome in melanoma. PLoS One (2013) 1.38

miR-191: an emerging player in disease biology. Front Genet (2014) 1.12

Targeting of YAP1 by microRNA-15a and microRNA-16-1 exerts tumor suppressor function in gastric adenocarcinoma. Mol Cancer (2015) 0.99

Melanoma risk loci as determinants of melanoma recurrence and survival. J Transl Med (2013) 0.94

miR-514a regulates the tumour suppressor NF1 and modulates BRAFi sensitivity in melanoma. Oncotarget (2015) 0.91

Control by a hair's breadth: the role of microRNAs in the skin. Cell Mol Life Sci (2012) 0.90

Differentially expressed wound healing-related microRNAs in the human diabetic cornea. PLoS One (2013) 0.90

MicroRNA expression profiling predicts clinical outcome of carboplatin/paclitaxel-based therapy in metastatic melanoma treated on the ECOG-ACRIN trial E2603. Clin Epigenetics (2015) 0.84

Curcumin intake affects miRNA signature in murine melanoma with mmu-miR-205-5p most significantly altered. PLoS One (2013) 0.81

RSK1 activation promotes invasion in nodular melanoma. Am J Pathol (2015) 0.80

MicroRNA-138 suppresses proliferation, invasion and glycolysis in malignant melanoma cells by targeting HIF-1α. Exp Ther Med (2016) 0.80

MicroRNAs in melanoma development and resistance to target therapy. Oncotarget (2017) 0.78

Revisiting determinants of prognosis in cutaneous melanoma. Cancer (2015) 0.77

How microRNAs modify protein production. J Invest Dermatol (2015) 0.77

Identification of microRNAs associated with invasive and aggressive phenotype in cutaneous melanoma by next-generation sequencing. Lab Invest (2017) 0.75

MicroRNA-9 suppresses the growth, migration, and invasion of malignant melanoma cells via targeting NRP1. Onco Targets Ther (2016) 0.75

Articles cited by this

Microarray analysis shows that some microRNAs downregulate large numbers of target mRNAs. Nature (2005) 48.95

Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. Proc Natl Acad Sci U S A (2004) 28.29

microRNAs exhibit high frequency genomic alterations in human cancer. Proc Natl Acad Sci U S A (2006) 8.24

A tumorigenic subpopulation with stem cell properties in melanomas. Cancer Res (2005) 7.86

Frequent mutation of BAP1 in metastasizing uveal melanomas. Science (2010) 7.47

An integrated approach to uncover drivers of cancer. Cell (2010) 4.53

Rate of growth in melanomas: characteristics and associations of rapidly growing melanomas. Arch Dermatol (2006) 4.51

Increasing burden of melanoma in the United States. J Invest Dermatol (2009) 4.43

A parsimonious model for gene regulation by miRNAs. Science (2011) 3.79

The promyelocytic leukemia zinc finger-microRNA-221/-222 pathway controls melanoma progression through multiple oncogenic mechanisms. Cancer Res (2008) 3.21

Common logic of transcription factor and microRNA action. Trends Biochem Sci (2004) 2.95

Gene expression signatures for tumor progression, tumor subtype, and tumor thickness in laser-microdissected melanoma tissues. Clin Cancer Res (2007) 2.62

miR-30b/30d regulation of GalNAc transferases enhances invasion and immunosuppression during metastasis. Cancer Cell (2011) 2.30

Identification of high-risk patients among those diagnosed with thin cutaneous melanomas. J Clin Oncol (2007) 2.06

miRNA expression profiling in melanocytes and melanoma cell lines reveals miRNAs associated with formation and progression of malignant melanoma. J Invest Dermatol (2009) 2.06

MicroRNA expression profiles associated with mutational status and survival in malignant melanoma. J Invest Dermatol (2010) 1.93

Signatures of microRNAs and selected microRNA target genes in human melanoma. Cancer Res (2010) 1.90

Multicenter Phase II trial of high-dose imatinib mesylate in metastatic melanoma: significant toxicity with no clinical efficacy. Cancer (2006) 1.75

In vivo microscopic features of nodular melanomas: dermoscopy, confocal microscopy, and histopathologic correlates. Arch Dermatol (2008) 1.69

CCR4-NOT deadenylates mRNA associated with RNA-induced silencing complexes in human cells. Mol Cell Biol (2010) 1.55

Functional dissection of the human TNRC6 (GW182-related) family of proteins. Mol Cell Biol (2009) 1.49

MicroRNA profiling reveals two distinct p53-related human pluripotent stem cell states. Cell Stem Cell (2010) 1.49

Musashi1 modulates mammary progenitor cell expansion through proliferin-mediated activation of the Wnt and Notch pathways. Mol Cell Biol (2008) 1.47

MicroRNAs and cellular phenotypy. Cell (2010) 1.34

Distinct clinical and pathological features are associated with the BRAF(T1799A(V600E)) mutation in primary melanoma. J Invest Dermatol (2006) 1.25

Histologic criteria for diagnosing primary cutaneous malignant melanoma. Mod Pathol (2006) 1.19

Hear the Wnt Ror: how melanoma cells adjust to changes in Wnt. Pigment Cell Melanoma Res (2009) 1.19

Developing a multidisciplinary prospective melanoma biospecimen repository to advance translational research. Am J Transl Res (2009) 1.17

Changes in the presentation of nodular and superficial spreading melanomas over 35 years. Cancer (2008) 1.14

Integrative genomics identifies molecular alterations that challenge the linear model of melanoma progression. Cancer Res (2011) 1.06

Musashi1 modulates cell proliferation genes in the medulloblastoma cell line Daoy. BMC Cancer (2008) 1.04

The contribution of nodular subtype to melanoma mortality in the United States, 1978 to 2007. Arch Dermatol (2011) 1.04

Altered molecular pathways in melanocytic lesions. Int J Cancer (2010) 1.03

The oncogenic RNA-binding protein Musashi1 is regulated by tumor suppressor miRNAs. RNA Biol (2011) 0.98

The epidermal and dermal origin of melanocytic tumors: theoretical considerations based on epidemiologic, clinical, and histopathologic findings. Am J Dermatopathol (2008) 0.96

Factors related to the presentation of thin and thick nodular melanoma from a population-based cancer registry in Queensland Australia. Cancer (2009) 0.94

Intestinal adenoma formation and MYC activation are regulated by cooperation between MYB and Wnt signaling. Cell Death Differ (2009) 0.91

Three roots of melanoma. Arch Dermatol (2008) 0.89

RASSF1A suppresses melanoma development by modulating apoptosis and cell-cycle progression. J Cell Physiol (2011) 0.89

Growth factors and oncogenes as targets in melanoma: lost in translation? Adv Dermatol (2007) 0.83

The classification of cutaneous melanoma. Hematol Oncol Clin North Am (2009) 0.82

Time trends in tumour thickness vary in subgroups: analysis of 6475 patients by age, tumour site and melanoma subtype. Melanoma Res (2009) 0.81

Can different genetic changes characterize histogenetic subtypes and biologic behavior in sporadic malignant melanoma of the skin? Cell Mol Life Sci (2003) 0.78

Articles by these authors

BRAF mutation predicts sensitivity to MEK inhibition. Nature (2005) 17.14

Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas. Nature (2007) 16.95

Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N Engl J Med (2012) 13.17

ESEfinder: A web resource to identify exonic splicing enhancers. Nucleic Acids Res (2003) 12.81

Large-scale sequence analysis of avian influenza isolates. Science (2006) 9.87

Chemokine signaling via the CXCR2 receptor reinforces senescence. Cell (2008) 7.65

Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N Engl J Med (2015) 7.51

Tet2 loss leads to increased hematopoietic stem cell self-renewal and myeloid transformation. Cancer Cell (2011) 7.37

Bcl-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: the Oblimersen Melanoma Study Group. J Clin Oncol (2006) 7.33

DNA methylation signatures identify biologically distinct subtypes in acute myeloid leukemia. Cancer Cell (2010) 6.72

Antibiotics in early life alter the murine colonic microbiome and adiposity. Nature (2012) 6.37

Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial. Lancet (2012) 6.21

Mad2 overexpression promotes aneuploidy and tumorigenesis in mice. Cancer Cell (2006) 5.88

An epi-allelic series of p53 hypomorphs created by stable RNAi produces distinct tumor phenotypes in vivo. Nat Genet (2003) 5.82

A novel tumour-suppressor function for the Notch pathway in myeloid leukaemia. Nature (2011) 5.78

Genome sequence of Shigella flexneri 2a: insights into pathogenicity through comparison with genomes of Escherichia coli K12 and O157. Nucleic Acids Res (2002) 4.92

An increased specificity score matrix for the prediction of SF2/ASF-specific exonic splicing enhancers. Hum Mol Genet (2006) 4.56

Ezh1 and Ezh2 maintain repressive chromatin through different mechanisms. Mol Cell (2008) 4.44

Aberrant miR-182 expression promotes melanoma metastasis by repressing FOXO3 and microphthalmia-associated transcription factor. Proc Natl Acad Sci U S A (2009) 4.00

Gamma-secretase inhibitors reverse glucocorticoid resistance in T cell acute lymphoblastic leukemia. Nat Med (2008) 3.98

Single cell behavior in metastatic primary mammary tumors correlated with gene expression patterns revealed by molecular profiling. Cancer Res (2002) 3.95

KIT as a therapeutic target in metastatic melanoma. JAMA (2011) 3.49

MicroRNA-377 is up-regulated and can lead to increased fibronectin production in diabetic nephropathy. FASEB J (2008) 2.75

Perspective: Malpractice in an academic medical center: a frequently overlooked aspect of professionalism education. Acad Med (2011) 2.68

Incidence of the V600K mutation among melanoma patients with BRAF mutations, and potential therapeutic response to the specific BRAF inhibitor PLX4032. J Transl Med (2010) 2.65

Analysis of BRAF and N-RAS mutations in metastatic melanoma tissues. Cancer Res (2003) 2.62

GenomeComp: a visualization tool for microbial genome comparison. J Microbiol Methods (2003) 2.62

Early diagnosis of cutaneous melanoma: revisiting the ABCD criteria. JAMA (2004) 2.58

Tissue-specific and reversible RNA interference in transgenic mice. Nat Genet (2007) 2.54

Pharmacodynamic effects and mechanisms of resistance to vemurafenib in patients with metastatic melanoma. J Clin Oncol (2013) 2.51

The histone variant macroH2A suppresses melanoma progression through regulation of CDK8. Nature (2010) 2.49

Control of chromosome stability by the beta-TrCP-REST-Mad2 axis. Nature (2008) 2.46

Phase II study of the MEK1/MEK2 inhibitor Trametinib in patients with metastatic BRAF-mutant cutaneous melanoma previously treated with or without a BRAF inhibitor. J Clin Oncol (2012) 2.45

miR-17-92 cluster accelerates adipocyte differentiation by negatively regulating tumor-suppressor Rb2/p130. Proc Natl Acad Sci U S A (2008) 2.42

Intra- and inter-tumor heterogeneity of BRAF(V600E))mutations in primary and metastatic melanoma. PLoS One (2012) 2.40

Relapse-specific mutations in NT5C2 in childhood acute lymphoblastic leukemia. Nat Genet (2013) 2.38

Hierarchical model of gene regulation by transforming growth factor beta. Proc Natl Acad Sci U S A (2003) 2.37

Declining p53 function in the aging process: a possible mechanism for the increased tumor incidence in older populations. Proc Natl Acad Sci U S A (2007) 2.36

Increasing incidence of rectal cancer in patients aged younger than 40 years: an analysis of the surveillance, epidemiology, and end results database. Cancer (2010) 2.34

Immune profile and mitotic index of metastatic melanoma lesions enhance clinical staging in predicting patient survival. Proc Natl Acad Sci U S A (2009) 2.32

PET/NIRF/MRI triple functional iron oxide nanoparticles. Biomaterials (2010) 2.31

miR-30b/30d regulation of GalNAc transferases enhances invasion and immunosuppression during metastasis. Cancer Cell (2011) 2.30

eIF4GI links nutrient sensing by mTOR to cell proliferation and inhibition of autophagy. J Cell Biol (2008) 2.26

Control of hematopoietic stem cell quiescence by the E3 ubiquitin ligase Fbw7. J Exp Med (2008) 2.19

Complete loss of the tumor suppressor MAD2 causes premature cyclin B degradation and mitotic failure in human somatic cells. Proc Natl Acad Sci U S A (2004) 2.19

A phase II multicenter study of ipilimumab with or without dacarbazine in chemotherapy-naïve patients with advanced melanoma. Invest New Drugs (2010) 2.09

Intraoperative assessment of endoscopic third ventriculostomy success. J Neurosurg Pediatr (2008) 2.09

Nipple-sparing mastectomy in patients with a history of reduction mammaplasty or mastopexy: how safe is it? Plast Reconstr Surg (2013) 2.08

Evolution of cranial epilepsy surgery complication rates: a 32-year systematic review and meta-analysis. J Neurosurg (2014) 2.03

Discovery of 1-(4-(4-propionylpiperazin-1-yl)-3-(trifluoromethyl)phenyl)-9-(quinolin-3-yl)benzo[h][1,6]naphthyridin-2(1H)-one as a highly potent, selective mammalian target of rapamycin (mTOR) inhibitor for the treatment of cancer. J Med Chem (2010) 2.00

Characterization of RNase R-digested cellular RNA source that consists of lariat and circular RNAs from pre-mRNA splicing. Nucleic Acids Res (2006) 2.00

Immunization of malignant melanoma patients with full-length NY-ESO-1 protein using TLR7 agonist imiquimod as vaccine adjuvant. J Immunol (2008) 2.00

Essential role for eIF4GI overexpression in the pathogenesis of inflammatory breast cancer. Nat Cell Biol (2009) 1.99

BiRD (Biaxin [clarithromycin]/Revlimid [lenalidomide]/dexamethasone) combination therapy results in high complete- and overall-response rates in treatment-naive symptomatic multiple myeloma. Blood (2007) 1.98

Epigenome-wide DNA methylation landscape of melanoma progression to brain metastasis reveals aberrations on homeobox D cluster associated with prognosis. Hum Mol Genet (2013) 1.95

Phase II trial of 17-allylamino-17-demethoxygeldanamycin in patients with metastatic melanoma. Clin Cancer Res (2008) 1.94

CCR7 signalling as an essential regulator of CNS infiltration in T-cell leukaemia. Nature (2009) 1.94

Aristolochic acid-associated urothelial cancer in Taiwan. Proc Natl Acad Sci U S A (2012) 1.82

The inducible deletion of Drosha and microRNAs in mature podocytes results in a collapsing glomerulopathy. Kidney Int (2011) 1.82

Genome-wide copy number profiling reveals molecular evolution from diagnosis to relapse in childhood acute lymphoblastic leukemia. Blood (2008) 1.79

Frequent p16-independent inactivation of p14ARF in human melanoma. J Natl Cancer Inst (2008) 1.78

FOXC1 is a potential prognostic biomarker with functional significance in basal-like breast cancer. Cancer Res (2010) 1.73

Integrated genomic analysis of relapsed childhood acute lymphoblastic leukemia reveals therapeutic strategies. Blood (2011) 1.67

chinmo is a functional effector of the JAK/STAT pathway that regulates eye development, tumor formation, and stem cell self-renewal in Drosophila. Dev Cell (2010) 1.67

microRNA-214 contributes to melanoma tumour progression through suppression of TFAP2C. EMBO J (2011) 1.66

Derivation of sarcomas from mesenchymal stem cells via inactivation of the Wnt pathway. J Clin Invest (2007) 1.66

Role of the chromobox protein CBX7 in lymphomagenesis. Proc Natl Acad Sci U S A (2007) 1.65

Genome-wide promoter extraction and analysis in human, mouse, and rat. Genome Biol (2005) 1.64

Blockade of miR-150 maturation by MLL-fusion/MYC/LIN-28 is required for MLL-associated leukemia. Cancer Cell (2012) 1.61

A role for mammalian Sin3 in permanent gene silencing. Mol Cell (2008) 1.59

Melanoma MicroRNA signature predicts post-recurrence survival. Clin Cancer Res (2010) 1.59

Fluorinated deoxyglucose positron emission tomography imaging in progressive metastatic prostate cancer. Urology (2002) 1.57

Knock down of HIF-1alpha in glioma cells reduces migration in vitro and invasion in vivo and impairs their ability to form tumor spheres. Mol Cancer (2010) 1.50

Is surgical excision necessary for the management of atypical lobular hyperplasia and lobular carcinoma in situ diagnosed on core needle biopsy?: a report of 38 cases and review of the literature. Arch Pathol Lab Med (2008) 1.49